Skip to main content

AtheroNova Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume46,155 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AHROQ News and Ratings via Email

Sign-up to receive the latest news and ratings for AtheroNova and its competitors with MarketBeat's FREE daily newsletter.

About AtheroNova

AtheroNova Inc., a development stage company, is engaged in the research, development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. The company develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. Its lead compound includes AHRO-001, an active pharmaceutical ingredient. The company also focuses on developing various applications for its patented and patents-pending therapies in market sectors that comprise cardiovascular disease, stroke, and peripheral artery disease. AtheroNova Inc. was founded in 2006 and is based in Irvine, California.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

2021st out of 2,050 stocks

Pharmaceutical Preparations Industry

767th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AtheroNova (OTCMKTS:AHROQ) Frequently Asked Questions

What stocks does MarketBeat like better than AtheroNova?

Wall Street analysts have given AtheroNova a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AtheroNova wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are AtheroNova's key executives?

AtheroNova's management team includes the following people:
  • Mr. Thomas W. Gardner, Chairman, CEO and Pres (Age 67, Pay $160k)
  • Dr. Randolph M. Johnson, Chief Operating Officer
  • Dr. Johannes Jacob Pieter Kastelein, Co-Principal Investigator & Member of The Medical Advisory Board (Age 67)

Who are some of AtheroNova's key competitors?

What is AtheroNova's stock symbol?

AtheroNova trades on the OTCMKTS under the ticker symbol "AHROQ."

How do I buy shares of AtheroNova?

Shares of AHROQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtheroNova's stock price today?

One share of AHROQ stock can currently be purchased for approximately $0.01.

How many employees does AtheroNova have?

AtheroNova employs 3 workers across the globe.

What is AtheroNova's official website?

The official website for AtheroNova is

Where are AtheroNova's headquarters?

AtheroNova is headquartered at 2301 DUPONT DRIVE SUITE 525, IRVINE CA, 92612.

How can I contact AtheroNova?

AtheroNova's mailing address is 2301 DUPONT DRIVE SUITE 525, IRVINE CA, 92612. The company can be reached via phone at 949-476-1100 or via email at [email protected]

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.